Zhang Jerry G, Carter Cedric J, Culibrk Brankica, Devine Dana V, Levin Elena, Scammell Kenneth, Weiss Sandra, Gyongyossy-Issa Maria I C
Canadian Blood Services and the Center for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
Transfusion. 2008 May;48(5):847-56. doi: 10.1111/j.1537-2995.2008.01645.x. Epub 2008 Feb 21.
Buffy-coat processing allows for the use of platelet additive solutions (PASs). PASs reduce plasma-associated transfusion reactions and conserve plasma for transfusion or fractionation. Platelet (PLT) storage in plasma was compared to storage in three commercially available PASs compared to assess their influence on in vitro laboratory variables.
Platelet concentrates (PCs) were prepared from leukoreduced pools of four buffy coats (BCPs) suspended in autologous plasma or one of PASs (Composol, Fresenius-Kabi; T-Sol, Baxter Corp.; or SSP+, MacoPharma). On Days 1, 2, 3, 5, and 7 of storage, samples were tested for PLT concentration, mean PLT volume (MPV), CD62P, morphology, pO2, pCO2, glucose, lactate and total protein concentration, pH, extent of shape change (ESC), and hypotonic shock response (HSR). Data were analyzed by analysis of variance (ANOVA) with repeated measures and t tests.
PLT recoveries from BCPs were higher (p < 0.05) with plasma than any PAS. Storage medium and duration did not affect PLT concentration or MPV over time. CD62P expression and morphology were significantly different among PCs pooled with different media. ANOVA showed (p < 0.05) differences among the rates of change of pCO2, pH, glucose consumption, lactate production, and ESC; PASs such as Composol and SSP+ offered excellent maintenance of pH and low rates of glucose consumption. PAS performed poorly in ESC and HSR compared to plasma. Correlation studies reveal far more significant correlations between variables of PLTs in PAS than in plasma.
Newer PASs, for example, SSP+ and Composol, can maintain PLT integrity and moderate metabolism similarly to plasma but offer consistently lower PLT recoveries and limited osmotic balance.
白细胞层处理允许使用血小板添加剂溶液（PASs）。PASs可减少与血浆相关的输血反应，并保存血浆用于输血或成分分离。将血小板（PLT）在血浆中的储存与在三种市售PASs中的储存进行比较，以评估它们对体外实验室变量的影响。
血小板浓缩物（PCs）由悬浮在自体血浆或一种PASs（Composol，费森尤斯卡比公司；T-Sol，百特公司；或SSP+，迈柯唯公司）中的四个白细胞层（BCPs）的白细胞滤除池制备而成。在储存的第1、2、3、5和7天，对样本进行PLT浓度、平均PLT体积（MPV）、CD62P、形态、pO2、pCO2、葡萄糖、乳酸和总蛋白浓度、pH、形状变化程度（ESC）和低渗休克反应（HSR）检测。数据通过重复测量方差分析（ANOVA）和t检验进行分析。
与任何PAS相比，血浆中BCPs的PLT回收率更高（p < 0.05）。随着时间的推移，储存介质和持续时间不影响PLT浓度或MPV。不同介质混合的PCs之间，CD62P表达和形态有显著差异。ANOVA显示（p < 0.05）pCO2、pH、葡萄糖消耗率、乳酸生成率和ESC的变化率之间存在差异；Composol和SSP+等PASs能很好地维持pH值且葡萄糖消耗率较低。与血浆相比，PAS在ESC和HSR方面表现较差。相关性研究表明，PAS中PLT变量之间的相关性远比血浆中的显著。
新型PASs，如SSP+和Composol，与血浆类似，可维持PLT完整性并适度代谢，但PLT回收率始终较低且渗透平衡有限。
